Cell and Gene Therapy Regulatory Affairs Summit

The Ultimate Chance to Tackle Regulatory Challenges in the Cell and Gene Therapy Space!

With over 5,000 cell and gene therapies in pre-clinical and clinical development worldwide, regulatory clarity is crucial for developers striving for efficient and seamless approvals in their first regulatory submissions. Leading innovators are pioneering new approaches, like in vivo gene editing, rapidly pushing products from the clinic to commercialization. This rapidly evolving field is now on a mission to learn from case studies and glean insights from the forefront to optimize regulatory processes from pre-IND to approval.

Introducing the inaugural Cell and Gene Therapy Regulatory Affairs Summit in Washington D.C. This event will unite biopharma experts across non-clinical,
clinical, and CMC regulatory domains in the cell and gene therapy sector. This is a uniquely positioned platform for the community to crystallize regulations, learn from the experiences of trailblazers, and engage in conversations to unravel regulatory bottlenecks.

Full Agenda - https://ter.li/3ir9uh

Don't miss this opportunity to gain exclusive insights from industry giants such as Orchard Therapeutics, AstraZeneca, Century Therapeutics, Bristol Myers Squibb, Cytolmmune Therapeutics, Prime Medicine, Verve Therapeutics, and more, as they work collaboratively to tackle the regulatory challenges facing the cell and gene therapy community.

Book Online (group discounts of up to 20% off available) - https://ter.li/vp9h4t

URLs:
Website: https://go.evvnt.com/2504368-0?pid=176 
Tickets: https://go.evvnt.com/2504368-1?pid=176 
Brochure: https://go.evvnt.com/2504368-3?pid=176 

Time: 8:00 AM - 3:30 PM

Prices:
Drug Developer Pricing | Conference + Workshop Day : USD 4197.00,
Drug Developer Pricing | Conference Only: USD 2999.00,
Start-Up and Academic Pricing | Conference + Workshop Day: USD 3597.00,
Start-Up and Academic Pricing | Conference Only: USD 2599.00,
Standard Pricing | Conference + Workshop Day: USD 5097.00,
Standard Pricing | Conference Only: USD 3699.00

Speakers: Annelise Brossel | Director, Regulatory Affairs and Quality Assurance | Vivet Therapeutics, Beth Mellen | Vice President, Regulatory Affairs and Quality | Voyager Therapeutics, Chris Sharpe | Vice President, Regulatory Affairs | Quell Therapeutics, David Uguen | Senior Vice President, Head of Regulatory Affairs | Orchard Therapeutics, Dayna LeSueur | Associate Director, Regulatory Affairs | Verve Therapeutics, Fubao Wang | Senior Vice President, Head of Regulatory Affairs | Prime Medicine, Jean-Philippe Combal | Chief Executive Officer | Vivet Therapeutics, Keith Wonnacott | Vice President, Regulatory Affairs | Lexeo Therapeutics, Mallory Scott | Associate Director, Regulatory, Chemistry, Manufacturing and Controls | Legend Biotech, Melody Dai | Vice President, Head of Regulatory Affairs and CMC | Novasenta, Monica Veldman | Director, Global Regulatory Policy | Alliance for Regenerative Medicine, Omer Butt | Vice President, Regulatory Affairs | CytoImmune Therapeutics, Sagi Nahum | Global Senior Director, Analytical Sciences CMC, Cell and Gene Therapy | Orgenesis, Sean Russell | Senior Vice President, Regulatory Affairs | Achilles Therapeutics, Seraphin Kuate | Director, CMC, CAR-T Cell Therapy | Bristol Myers Squibb, Shirley Bartido | Director, Global Regulatory Affairs and Cell Therapy Oncology | Takeda Pharmaceuticals, Stephanie Woodall | Vice President, Quality and Regulatory | Abata Therapeutics, Tim Taps | Senior Director, Head of Regulatory Affairs, Regulatory Strategy, and Operations | Century Therapeutics, Wade Atkins | Regulatory Affairs Specialist | National Institute of Health, Yao-Yao Zhu | Director, Global Regulatory Affairs | AstraZeneca